Scott E. Eggener to Early Detection of Cancer
This is a "connection" page, showing publications Scott E. Eggener has written about Early Detection of Cancer.
Connection Strength
3.163
-
Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196.
Score: 0.447
-
Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3.
Score: 0.402
-
Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55.
Score: 0.384
-
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23.
Score: 0.377
-
National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
Score: 0.344
-
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43.
Score: 0.282
-
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
Score: 0.171
-
How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137.
Score: 0.140
-
Editorial Comment. J Urol. 2020 08; 204(2):287.
Score: 0.133
-
AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838.
Score: 0.108
-
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.
Score: 0.093
-
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4.
Score: 0.076
-
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.
Score: 0.041
-
Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63.
Score: 0.041
-
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53.
Score: 0.041
-
Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974.
Score: 0.031
-
African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.
Score: 0.027
-
Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397.
Score: 0.025